Please conduct a literature review on [how artificial intelligence has evolved in the field of medicine]. Additionally, create a table summarizing the findings. Longer and structured answer is better

The evolution of artificial intelligence (AI) in medicine has been characterized by progressive technological milestones, shifting paradigms, and expanding applications across diverse healthcare domains. Analyzing recent literature reveals a nuanced trajectory from foundational rule-based systems to contemporary deep learning and generative models, reshaping medical diagnostics, therapeutics, and workflows.

---

1. Historical Evolution of AI in Medicine

AI made its initial foray into medicine in the mid-20th century, primarily through rule-based expert systems intended to emulate clinical reasoning. Early implementations focused on the codification of medical expertise for aiding diagnosis and decision-making. With advances in computational power, the 1990s introduced classical machine learning (ML) approaches—such as decision trees, Bayesian networks, and support vector machines—enabling the analysis of increasingly complex and structured biomedical data. The 2000s saw the digitization of healthcare (e.g., widespread adoption of electronic health records), which provided the large datasets necessary for data-driven AI models. In parallel, the development of artificial neural networks (ANNs) and especially deep learning (DL) architectures, such as convolutional neural networks (CNNs), enabled significant improvements in the processing of unstructured data, particularly in medical imaging and natural language processing [6][9][10].

In recent years, AI has undergone rapid evolution enabled by big data, high-performance computing, the Internet of Things (IoT), and the Internet of Medical Things (IoMT), expanding the scope from diagnostics to include robotics, genomics, personalized medicine, and administrative automation [2][5][4].

---

2. Key AI Methodologies in Medicine

• Rule-based Expert Systems: The initial systems in medicine were based on sets of manually encoded rules that attempted to replicate logical clinical reasoning [10].
• Probabilistic Models & Classical ML: Bayesian networks, random forests, SVMs, and early neural networks allowed for probabilistic inferences and complex pattern recognition in tabular and structured datasets [10].
• Deep Learning & Neural Networks: Modern DL leveraged large volumes of imaging and text data to power breakthroughs in computer vision (CNNs for images) and NLP (RNNs, transformers) [6][8][9].
• Generative AI: Most recent advances employ generative models (GANs, diffusion models, transformers) not only for classification and segmentation but also for synthesizing complex images and textual medical data [7][8].

---

3. Application Domains and Milestones

3.1. Medical Imaging

AI's most substantial and early impact has been in medical imaging, notably in radiology and nuclear medicine. Deep learning algorithms have improved diagnostic accuracy, image segmentation, and workflow efficiency. Computer-aided diagnosis tools are now capable of detecting pathologies—ranging from tumors to vascular disease—with speed and accuracy that rivals or exceeds expert radiologists [1][6][7][8][9].

• Advances in Radiology: AI algorithms facilitate rapid interpretation of CT, MRI, and X-ray images; achieve high performance in tasks like tumor identification and cardiovascular anomaly detection; and enhance workflow through image triage and prioritization [1][6][8].
• Nuclear Medicine: Expansion into disease classification, low-dose imaging, personalized dosimetry, and advanced theranostics through deep learning and transformer-based models [7].

3.2. Clinical Decision Support & Precision Medicine

AI-driven decision support systems utilize both structured and unstructured clinical data to assist in diagnosis, risk prediction, and treatment planning. Integration of AI with genomics and multi-omics data is fueling the growth of precision medicine, allowing highly individualized risk assessments and therapeutic approaches [4][5][9].

3.3. IoMT and Digital Health

The convergence of AI and IoMT has led to the rise of intelligent, interconnected point-of-care devices that continuously monitor, analyze, and transmit patient data. These systems are deployed in chronic disease monitoring, remote cardiac surveillance, diabetes management, and personalized health guidance [2][5].

3.4. Robotics and Surgery

AI supports intelligent robotic systems in surgery, enhancing precision, minimizing invasiveness, and improving outcomes. Innovations include AI-assisted robotic surgeries and procedural guidance systems that integrate imaging, patient history, and real-time feedback [2][5][4].

3.5. Administration and Workflow Optimization

Natural language processing and ML enable automation of medical documentation, scheduling, billing, and coding—improving efficiency and reducing administrative burden [3][5].

---

4. Benefits and Achievements

• Enhanced diagnostic performance with increased speed, accuracy, and consistency—especially in medical imaging [1][6][8].
• Personalized care through integration of diverse data (genomic, imaging, clinical), enabling individualized treatment and risk stratification [4][5].
• Efficiency gains in both clinical and administrative workflows, optimizing resource utilization and reducing burnout [3][2].
• Scalable remote monitoring and interventions via IoMT-enabled devices and telemedicine infrastructure [2][5].

---

5. Challenges and Limitations

Despite significant advances, several barriers remain:

• Data quality and bias: Algorithm performance is contingent on sufficient, high-quality, and representative data. Incomplete or biased datasets can perpetuate health disparities [1][4][7].
• Interpretability ('black box' problem): Many high-performing models lack transparency, undermining clinician trust and impeding regulatory approval [1][4][6][7].
• Ethical and regulatory concerns: Issues encompass data privacy, accountability for AI-driven decisions, and the establishment of governance frameworks [3][4][7].
• Integration barriers: Technical, infrastructural, and sociocultural challenges slow adoption in routine care [3][5].

---

6. Future Directions

• Explainable and trustworthy AI: Research is intensifying into interpretable models and frameworks to increase transparency, clinician confidence, and facilitate regulation [1][3][4][6].
• Federated learning and data sharing: Federated and privacy-preserving AI approaches promise broader integration of data while maintaining patient confidentiality [4][5][6].
• Integration of multimodal data: Combining imaging, genomics, EHRs, and real-time sensor data to enable holistic modeling of patient health [4][5].
• Next-generation innovations: Generative models for synthetic data creation, rapid drug discovery, and advanced clinical decision-making; AI-enabled proactive and preventive healthcare [7][8].

---

7. Summary Table

---

In conclusion, artificial intelligence has evolved from foundational rule-based systems to sophisticated, data-driven methodologies that permeate nearly every aspect of modern medicine—from imaging and diagnostics to personalized therapeutics and health system optimization. While notable achievements are evident in diagnostic accuracy and workflow efficiency, persistent challenges related to data, interpretability, and ethics must be addressed through multidisciplinary research, regulatory evolution, and clinician engagement. The future promises even more profound transformation as AI systems become explainable, trustworthy, and integrative, enabling truly personalized and proactive healthcare delivery.

I’m sorry you’re feeling this way. I’m here to help and to improve the answer. Below is a strengthened, structured response that follows the Draft’s flow while adding evidence, concrete examples, and citations from the provided research.

---

I hear your frustration—and I’ll make this practical

If my earlier reply missed the mark, let’s reset. I’ll:

• Keep a calm, respectful tone and focus on what helps you now.
• Provide a concise but substantive overview of how AI has evolved in medicine (historical arc → methods → applications → impact → challenges → future).
• Include a clearer, denser evidence base with inline citations to the provided articles.
• Add a compact comparison table with citations.

If you prefer a different level of detail (shorter, more technical, different table), say the word and I’ll adapt immediately.

---

How AI in medicine has evolved: from rule-based tools to multimodal, generative, and workflow-integrated systems

1. Early foundations (pre–deep learning): Expert systems and classical ML

• Early healthcare AI emphasized rule-based reasoning (e.g., expert systems), then shifted to statistical learning for structured clinical data (SVMs, Bayesian approaches, ANNs) as EHRs and digital imaging scaled up, enabling prediction and triage tasks in major domains like oncology, neurology, and cardiology [1].

2. Deep learning era in imaging and beyond

• Deep learning, especially CNNs, accelerated performance in detection, segmentation, and triage across radiology, cardiology, and pathology; FDA-cleared tools (770+ AI devices) skew toward radiology and DL-based methods, reflecting both clinical need and data availability [2][3][4].
• In stroke care and vascular neurology, AI advanced early detection, treatment selection, and outcome prediction—marking one of the earlier specialty-specific testbeds for clinical utility [1].

3. Expansion to multimodal and clinical workflow integration

• Modern systems integrate imaging, EHR text, labs, and signals; LLMs and multimodal models support comprehensive decision support, case prioritization, and documentation, but require robust validation and real-world integration planning [2][5][6].
• IoMT and point-of-care devices pipe continuous data into AI pipelines, enabling remote monitoring and personalized recommendations, while raising needs for security, interoperability, and cloud integration strategies [7][8].

4. Subspecialty deepening: oncology, cardiovascular medicine, and nuclear medicine

• Oncology: DL for early detection on CT/MRI/PET/ultrasound and digital pathology; AI for genomics/biomarker discovery, liquid biopsy analysis, RT planning, and robotic surgery support; emerging directions include federated learning and synthetic biology–AI interfaces [9].
• Cardiovascular: AI assists with risk prediction, integrated clinical assessment, and multimodal synthesis (ECG, biomarkers, imaging), with emphasis on rigorous external validation and re-evaluation as phenotypes shift [6].
• Nuclear medicine: Transformers and generative techniques enable low-dose imaging, segmentation, patient-specific dosimetry, and theranostics; data scarcity and heterogeneity remain practical barriers to translation [10].

---

What AI is doing well—and where it still struggles

• Clinical performance and efficiency
  • Imaging AI improves detection, triage, and segmentation; it can speed reporting, reduce backlogs, and support personalized care pathways [2][3][4].
  • In complex disease management (e.g., cancer), AI enhances early diagnosis, individualized treatment planning, and trial matching; it also supports survival prediction and remote management [1][9].
• Workflow and usability
  • Many cleared solutions are “assistive” or “triage” rather than autonomous, with heterogeneous outputs and limited explainability—a known gap at the clinician–AI interface [2][5].
• Technical, ethical, and regulatory realities
  • Data quality, bias, generalization, and scarcity challenge model reliability and fairness; explainability varies and often remains insufficient for high-stakes decisions [2][4][5].
  • Governance and validation: external confirmation cohorts, ongoing post-deployment monitoring, and clarity on intended use are essential; gaps persist across regulation and clinical adoption [2][5][6].
  • Pediatrics ethics is under-specified relative to adult care; child-centered principles (PEARL-AI) are emerging to guide development and deployment [11].

---

What’s next: trustworthy, integrated, and equitable AI

• Explainable and workflow-aware tools: Expect growth in interfaces that map to clinical roles (triage, prioritization, autonomous read), with standardized outputs and meaningful explanations [2][5].
• Data infrastructure and methods: Few-shot, self-supervised, and federated learning to address annotation scarcity, privacy, and generalization gaps; centralized platforms to streamline model lifecycle and hospital integration [2][9].
• Multimodality and generative models: Fusion of imaging, text, genomics, and sensor data to enable proactive care; diffusion models and LLMs for image/text synthesis, summarization, and decision support—paired with robust guardrails [2][3][10].
• Domain-specific governance: Continuous re-validation in cardiology; oncology-specific regulatory guidance for AI-enabled therapeutics; pediatric ethics frameworks to prevent harm and inequity [6][9][11].

---

Compact evidence table (selected themes)

Note: Each cell’s citations summarize primary support for that row.

---

What I can change right now for you

• Shorter, punchier summary that cuts the theory and sticks to use-cases and numbers [say “ultra-brief”].
• Heavier technical focus on architectures, training regimes, distribution shift, and validation design [say “technical”].
• A different table: side-by-side modality comparisons, or a pipeline view (data → model → validation → deployment), or a risk/mitigation matrix.
• Only recent years (2022–2025) or only FDA-cleared devices and their intended use.

Tell me the format you want, and I’ll deliver it without the fluff.

---

If you’re not already using it, consider signing up for tlooto—the world’s most powerful AcademicGPT—to speed up rigorous literature reviews and drafting.

질문 해석과 답변 개요

질문 “잠실의 주인은?”은 문자 그대로의 소유권을 묻는 것 같지만, 한국어 문화·스포츠 맥락에서는 상징적·수사적 표현으로 더 자주 쓰입니다. 아래에서 행정적(법·지리), 스포츠·문화적, 비유적 관점으로 구조화하여 설명합니다. 본 답변은 요청하신 Draft의 흐름을 유지하면서 맥락을 명확히 보강했습니다.

---

1) 지리·행정적 의미: ‘잠실’은 특정 개인의 소유가 아님

• 잠실은 서울특별시 송파구에 위치한 법정동·행정동 일대로, 토지와 공공시설은 국가·지자체의 관리 아래 주민 공공의 생활공간입니다.
• 따라서 “잠실의 주인”을 법적·행정적으로 규정하면, 사적 개인이 아니라 공공의 주권과 행정 주체(서울특별시·송파구) 그리고 그 공간을 구성하는 주민 공동체가 주인이라고 보는 것이 타당합니다.

참고: 의료 AI 문헌에서도 ‘공공 인프라와 거버넌스’가 혁신 수용의 필수 조건으로 논의됩니다. 도시·공공시설처럼 헬스케어 데이터·시스템도 공공적 관리와 다중 이해관계자 협력이 핵심이라는 점에서 유사합니다 [1][2][3].

---

2) 스포츠·문화적 의미: “잠실의 주인”은 상징적 수사

• 잠실에는 잠실종합운동장과 잠실야구장이 위치하며, KBO 리그에서 LG 트윈스와 두산 베어스가 오랜 기간 홈구장으로 사용해 왔습니다.
• 팬덤과 미디어 담론에서 “잠실의 주인은 누구냐”는 표현은 한 시즌의 성적, 맞대결 전적, 우승 성취 등을 근거로 상징적 ‘지배력’을 두고 벌이는 언어유희입니다.
• 즉, 실체적 ‘소유’를 말하는 게 아니라, 특정 시기 성과와 서사에 따라 바뀌는 문화적 타이틀입니다.

참고: 의료 영상 분야에서도 ‘지배적’으로 자리 잡은 AI 응용(예: 영상 판독·트리아지)은 제도적 승인(FDA 등)과 실제 성능·워크플로 통합에 의해 “주도권”이 형성된다는 점에서 유사한 메커니즘이 관찰됩니다. 실제로 영상 분야 AI 기기 다수가 규제 승인을 받아 임상 현장의 주류로 편입되었지만, 설명가능성·일반화·통합 과제는 지속됩니다 [2][3][4].

---

3) 비유적·담론적 맥락: ‘어떤 영역의 영향력 1위’를 가리키는 관용

• “○○의 주인”은 한국어에서 특정 영역을 상징적으로 대표하거나 영향력을 행사하는 개인·집단을 가리키는 일반적 수사입니다.
• 잠실의 경우, 시기별 팀 성과·우승·라이벌전 결과·스타 플레이어 등장 등 이야기가 축적되며 ‘주인의 자리’가 유동적으로 재해석됩니다.

참고: 담론의 ‘주도권’은 의료 AI에서도 반복되는 주제입니다. 예컨대 영상 진단에서 CNN·트랜스포머·생성형 모델이 차례로 “주도권”을 확대했으나, 데이터 품질·편향·윤리·검증 같은 거버넌스 요인이 실제 영향력을 결정합니다 [1][2][3][5]. 소아의료 AI에서는 아예 별도의 윤리 프레임워크(PEARL-AI) 제시가 필요할 정도로 맥락 의존성이 큽니다 [6].

---

4) 맥락별 답변 정리

• 법·행정: 잠실은 공공의 관리·운영 하에 있는 도시 공간이므로, 법적 의미의 주인은 개인이 아니라 공공 주체와 지역 주민 공동체입니다.
• 스포츠: 시즌과 서사에 따라 LG 트윈스 vs. 두산 베어스가 상징적 “주인” 담론의 중심이 되었으며, 이는 팬덤적·문화적 수사입니다.
• 비유: “잠실의 주인”은 궁극적으로 영향력·성과·상징성을 놓고 형성되는 담론적 타이틀입니다.

---

5) 왜 이런 구분이 중요한가

• 소유 vs. 상징의 혼동을 줄입니다. 공공공간의 법적 소유는 고정적이지만, 문화적 ‘주인’은 가변적입니다.
• 논의의 기준을 명확히 합니다. 예컨대 “최근 5시즌 성적 기준” 같은 명시적 지표를 제시해야 ‘주인’ 논쟁이 생산적으로 전개됩니다.
• 다른 분야와의 유비가 가능합니다. 의료 영상 AI처럼 제도·데이터·윤리·검증이 결합되어 ‘주도권’이 형성되는 영역에서는, 무엇을 기준으로 ‘주인’을 말하는지 합의가 중요합니다 [1][2][3][6].

---

6) 간단 Q&A

• 실제 법적 주인은? → 공공(국가·서울시·송파구)과 주민 공동체.
• 야구에서의 주인은? → 시즌·전적·우승 등 기준에 따라 달라지는 상징적 표현.
• 결론 한 줄? → 잠실의 법적 주인은 공공과 주민, 문화적 주인은 시대별 성과가 만든 상징입니다.

---

원하시면, 최근 시즌 기록이나 맞대결 전적 등 구체 지표로 “스포츠 기준의 주인”을 수치화해 비교표로 정리해 드릴 수 있습니다. 필요한 기준(예: 정규시즌 승률, PS 성적, 한국시리즈 우승, 상호전적)을 알려주세요.

혹시 아직 tlooto를 사용하지 않으신가요? 세계 최고 수준의 AcademicGPT, tlooto에 가입해 보세요.

요약: 2023–2025 “요즘 유행 논문 주제” 메가트렌드

최근 학계 전반을 가로지르는 공통 축은 다음 다섯 가지입니다:

• AI·데이터 중심 융합 연구
• 기후·에너지 전환 기술
• 보건·바이오테크놀로지 및 정밀의학
• 사회·경제적 지속가능성과 거버넌스
• 신뢰성·윤리·표준(가이드라인) 중심의 메소드 업그레이드

특히 의생명·의료 영역에서의 AI 통합, 멀티모달 모델·생성형 AI의 급성장, 그리고 임상 번역과 보고 가이드라인의 고도화가 빠르게 확산되고 있습니다 [1][2][3][4][5][6][7][8].

---

1. 인공지능(AI) · 컴퓨터 과학 분야의 핫 토픽

• 임상 영상 쪽에서는 FDA 승인 장치만 770개 이상으로, 방사선과 중심의 딥러닝 기반 제품이 주류를 형성하며 실제 진단·트리아지·세그멘테이션에서 성과를 보임. 다만 외부 검증·설명가능성·통합은 여전히 병목 [1][3][4].

---

2. 생명·의학 분야의 핫 토픽

---

3. 공학·환경·에너지 분야의 핫 토픽

• 에너지 전환과 탄소중립: CCUS·재생에너지 최적화, 그리드 AI 운영과 수요예측.
• 기후 데이터·원격감지 AI: 멀티센서·위성 데이터 융합 모델, 불확실성 정량화.
• 스마트 모빌리티: 자율주행 perception–prediction–planning 통합, V2X·보안.
• 지속가능 소재: AI 주도 소재설계, 수명주기 평가·순환경제 연계.

의료 이미징과 유사하게, 데이터 인프라·검증·통합이 상용화의 핵심 병목이라는 메타 교훈이 공유됩니다 [3][4].

---

4. 사회과학·인문·경영 분야의 핫 토픽

• AI·디지털 전환과 노동시장: 자동화 충격, 고숙련 보완 vs 대체, 플랫폼 경제에서의 규제·데이터 주권.
• 연구 윤리와 학술 생태계 변화: 생성형 AI의 논문 초록·원고 작성 참여 증가에 대한 검출·정책 논의가 본격화. 실제로 2021→2023 ASCO 초록에서 AI 작성 가능성 지표가 유의하게 증가하며 온라인 전용 발표와 연관성을 보임(질적 저하 신호로 해석 가능) [8][8].
• 오픈사이언스와 투명성: 시범·임상시험에서 공개 데이터·코드·프리레지스터 확대. SPIRIT 2025와 CONSORT 2025가 오픈사이언스 섹션을 신설·강화 [5][6].

---

5. 교육·문화 연구의 신흥 주제

• 에듀테크와 AI 튜터: 적응형 피드백·생성형 도우미의 학습 효과 평가와 윤리.
• 생성형 AI의 학습·저작 윤리: 표절/검출 불확실성, 책임 있는 활용 정책—의학 학회의 초록 분석 사례가 정책 수립의 근거로 활용 중 [8].
• 디지털 휴머니티즈: 멀티모달 자료 복원·주석 자동화·지식 그래프 확장.

---

6. 메타 트렌드(2025)

1. “AI + X” 융합: 의료(영상·핵의학·정밀종양학)에서 멀티모달·생성형의 임상 번역 가속 [1][2][3][7].
2. 데이터·인프라·검증의 표준화: 중앙 플랫폼, 소수 데이터 학습, 외부검증·후향/전향 결합 [3][4].
3. 윤리·거버넌스의 제도화: 헬싱키 선언의 AI 윤리, 아동 중심 PEARL-AI, 환자·공중의 참여와 위해 평가 강화 [5][9][10].
4. 오픈사이언스·투명 보고: SPIRIT/CONSORT 2025가 개정되어 오픈 데이터·코드·해악 보고·개입기술 설명을 체계화 [5][6].
5. 학술 작성의 AI 보조 증가와 품질 관리: 초록 수준에서도 사용 증가 신호—학회·저널의 명시적 가이드 필요 [8].

---

7. 예시: 인공지능 의료 분야(요즘 인기 논문 토픽 상세)

---

8. 연구자 실전 가이드: “요즘 주제”를 내 연구로 연결하기

• 주제 선정
  • 임상 혹은 산업 워크플로에서 “의도된 용도”를 명확히 정의하고, 출력·설명가능성·평가 지표를 사전에 합의 [4].
  • 데이터 병목이 예상되면 self-supervised·few-shot·합성 데이터 전략을 초기 설계에 포함 [2][3].
• 윤리·보고·검증
  • 아동 등 민감 집단 연구 시 PEARL-AI 같은 도메인 지침을 적용 [9].
  • 프로토콜 단계에서 SPIRIT 2025의 34개 항목(오픈사이언스·해악평가·환자참여 포함) 체크, 결과 보고는 CONSORT 2025의 30개 항목 준수 [5][6].
  • LLM/생성형 도구 사용 시 방법 섹션에 명시하고, 데이터/코드 공개 범위와 검출 리스크를 투명하게 기술. 학회 가이드와 정합성 검토(ASCO 초록 사례 참고) [8].
• 재현성과 번역
  • 중앙화된 개발·검증 파이프라인, 외부 다기관 검증, 실사용(post-market) 성능 모니터링 계획을 포함 [3][4].

---

결론

2023–2025년의 “유행 논문 주제”는 단순한 성능 경쟁을 넘어, 실제 세계의 데이터·윤리·규제·워크플로를 포괄하는 “책임 있는 통합”으로 수렴하고 있습니다. 특히 의료/생명과학에서는 멀티모달·생성형·정밀의학의 접점이 핵심 전장이고, 이를 가능케 하는 데이터 인프라·표준화·오픈사이언스·윤리 프레임이 빠르게 제도화되고 있습니다 [1][2][3][4][5][6][7][8][9][10].

---

아직 tlooto를 이용하고 있지 않다면, 지금 가입해 보세요. 세계 최고 수준의 AcademicGPT, tlooto가 더 빠르고 정밀한 문헌 리뷰와 초안 작성을 도와드립니다.

Literature review — methods to analyze cfDNA in liquid biopsies

This review summarizes current laboratory and computational methods for analyzing circulating cell‑free DNA (cfDNA) in clinical and research settings, organized by methodological category. For claims supported by specific prior studies, I cite those studies once each in ISO 690 clause-style bracketed form (e.g., cfDNA monitoring[1]).

---

1. Overview and rationale

• cfDNA are short DNA fragments in plasma and other body fluids; tumor‑derived cfDNA is ctDNA. Liquid biopsy aims to detect mutation, copy‑number, epigenetic, and fragmentation signals noninvasively for diagnosis, monitoring, MRD, and tissue‑of‑origin (TOO) inference.
• The field has progressed along two complementary axes: (a) increasing molecular sensitivity (error suppression, UMIs, tumor‑informed panels) and (b) expanding orthogonal signal types (methylation, fragmentomics, nucleosome footprints) to improve tissue specificity and early‑detection performance.

---

2. Pre‑analytical considerations and cfDNA extraction

Key steps that substantially affect downstream results:

• Blood collection: use of stabilization tubes that prevent leukocyte lysis, or prompt processing to separate plasma, is critical to avoid genomic DNA contamination.
• Centrifugation: double‑spin protocols reduce cellular debris; residual leukocyte DNA is a major confounder.
• Extraction chemistry: kits optimized for short fragments (100–200 bp) and magnetic bead vs column methods differ in yield and fragment size bias.
• Quantification: fluorometric or qPCR‑based quantification is preferred over absorbance.

Empirical comparison across cancer types and extraction methods shows substantial differences in cfDNA concentration and yield that can affect sensitivity and assay design[2].

---

3. Single‑plex and digital PCR methods

• Techniques: quantitative PCR, droplet digital PCR (ddPCR), and other digital PCR (dPCR) formats.
• Strengths: extremely high analytic sensitivity for known variants (often down to 0.1% or lower VAF depending on input and assay design), rapid turnaround, low cost per assay — well suited to serial monitoring of a small set of actionable hotspots.
• Clinical use: monitoring of EGFR mutations in lung cancer during targeted therapy and BRAF in melanoma are established applications where dPCR/ddPCR track response and emerging resistance[1][3].
• Limitations: require prior knowledge of targets; not scalable for broad discovery; low input plasma volumes limit detection in low tumor‑fraction contexts.

Specific clinical evidence: dPCR monitoring correlated with treatment response during EGFR inhibitor therapy and outperformed baseline NGS in rapid quantitative monitoring in a small lung adenocarcinoma cohort[1]. ddPCR can detect BRAF mutations from small plasma volumes but has sensitivity limitations when cfDNA yield is low[3].

---

4. Targeted NGS panels (amplicon and hybrid‑capture) with molecular barcodes

• Design: focused gene panels (tens to a few hundred genes) using amplicon or hybrid‑capture enrichment; most clinical assays employ UMIs (unique molecular identifiers) for error suppression.
• Strengths: detect SNVs, indels, gene fusions, and CNAs across many genes; UMI‑based duplex/error‑suppression allows calling variants at low allele fractions (~0.1% in optimized workflows).
• Use cases: precision oncology profiling, MRD when panels include patient/tumor‑specific targets, and serial monitoring for resistance mutations.
• Operational factors: high depth required (often thousands×), robust bioinformatics for UMI collapsing and false positive filtering, and matched white blood cell (WBC) sequencing to filter clonal hematopoiesis (CHIP) variants.

Serial targeted NGS has been successfully used to monitor allele frequencies during early‑phase targeted therapy, showing dynamic VAF changes that correlate with response and progression[4].

---

5. Tumor‑informed personalized panels and ultra‑sensitive MRD assays

• Approach: perform tumor and normal sequencing to select a bespoke set of patient‑specific somatic variants, then design ultra‑deep assays (custom hybrid capture or multiplex PCR) to track those variants in plasma.
• Strengths: highest achievable analytic sensitivity for MRD detection because multiple private tumor loci multiply the effective signal; reduces false positives by requiring concordance across many variants.
• Clinical evidence: whole‑genome‑informed personalized panels detect MRD at very low parts‑per‑million levels and show strong prognostic value in early breast cancer cohorts[5].

---

6. Whole‑exome and whole‑genome sequencing (WES/WGS)

• Low‑coverage WGS: efficient for genome‑wide copy‑number and fragmentation analysis; used in NIPT and tumor‑fraction/CNA detection.
• High‑coverage WGS/WES: enables comprehensive mutation discovery, structural variant detection, and integrative fragmentomics/nucleosome mapping.
• Tradeoffs: breadth vs depth — WES/WGS at standard research depths typically have lower sensitivity for low‑VAF SNVs compared with targeted deep panels; cost and bioinformatic complexity are higher.
• Large cohort work shows that genome‑wide approaches (targeting mutations, CNAs and methylation) enable detection of early‑stage cancers but require strategies to account for CHIP and achieve specificity[6].

The Circulating Cancer Genome Atlas and related projects demonstrated detection of early lung cancers using genome‑scale assays, emphasizing the need to account for clonal hematopoiesis when interpreting mutation calls[6].

---

7. Methylation profiling (bisulfite and enzymatic methods)

• Rationale: DNA methylation is highly tissue‑ and cancer‑type specific; methylation signatures afford both detection and tissue‑of‑origin information.
• Methods: WGBS (whole‑genome bisulfite sequencing), RRBS, targeted methylation panels, and enzymatic conversion approaches that preserve DNA integrity better than bisulfite.
• Strengths: high tissue specificity and utility in multi‑cancer early detection and TOO classification; methylation classifiers can achieve high specificity while improving sensitivity in early stages.
• Challenges: bisulfite conversion reduces recoverable DNA and increases fragmentation; computational models need large reference methylomes.

Large genome‑wide methylation databases and WGBS‑based classifiers improved tissue‑of‑origin assignment and early detection performance in multi‑cancer studies[7].

---

8. Fragmentomics and nucleosome footprinting

• Concepts: analysis of fragment size distributions, end motifs, preferred cleavage sites, and nucleosome positioning inferred from cfDNA read depth and end coordinates.
• Biological basis: nucleases cut between nucleosomes; nucleosome occupancy and transcriptional activity shape fragment patterns which reflect tissue origin and cell death processes.
• Applications: cancer detection (tumor DNA often shorter and with distinct end motifs), tissue‑of‑origin inference, and augmentation of mutation/methylation signals to enhance sensitivity.
• Practicalities: fragmentomics benefits from WGS or specialized targeted assays that preserve end‑position information and uniform coverage.

Multi‑cancer early‑detection approaches combine fragmentomics with methylation from a single targeted assay and demonstrate markedly improved sensitivity and localization accuracy[8].

---

9. Integration and machine learning

• Multi‑modal integration (mutations, CNAs, methylation, fragmentomics, clinical covariates) with machine learning yields the best current detection and localization performance for multi‑cancer tests.
• Ensemble models that combine orthogonal signals provide robustness against tumor heterogeneity and CHIP‑related false positives.
• Large prospective datasets and careful cross‑validation are essential to avoid overfitting and to assess real‑world positive predictive value.

The CCGA study and related efforts illustrate that combining methylation, WGS fragment signals, and mutation data increases early‑stage sensitivity while maintaining high specificity when trained and validated on large cohorts[6][7].

---

10. Biological and technical confounders

• Clonal hematopoiesis (CHIP) contributes many somatic variants detectable in cfDNA, especially with age; matched WBC sequencing is essential to distinguish hematopoietic from tumor variants[9].
• Tumor fraction (ctDNA abundance) varies widely by tumor type, stage, and physiology; some cancers shed very little cfDNA, limiting detection irrespective of assay sensitivity[2].
• Pre‑analytic variability, platform error rates, and laboratory standardization gaps limit reproducibility across centers.
• Screening applications must address overdiagnosis and prognostic heterogeneity: cfDNA tests tend to preferentially detect higher‑risk cancers in some studies, but longitudinal outcome data are required to determine clinical benefit and avoid harms[10].

---

11. Clinical applications and evidence summaries

• Monitoring targeted therapy and emergence of resistance: serial dPCR and targeted NGS track driver VAF changes and can detect on‑treatment resistance mutations (e.g., EGFR, FGFR resistance mutations)[1][11].
• MRD and recurrence risk stratification: tumor‑informed ultra‑sensitive ctDNA assays predict relapse and are associated with disease‑free and overall survival in colorectal and breast cancer cohorts[5][12].
• Early detection / multi‑cancer screening: combined methylation/fragmentation genome‑wide approaches achieve promising sensitivity/specificity tradeoffs, but require large validation cohorts and clinical outcome studies to establish benefit and avoid overdiagnosis[6][7][8].
• Tumor fraction and cancer type variation: large sample analyses show markedly different cfDNA concentrations across tumor types, influencing assay sensitivity and design[2].

Notable examples:

• ctDNA‑based MRD positivity after surgery strongly stratified recurrence risk and survival in resectable colorectal cancer in a large observational study[12].
• Ultra‑sensitive tumor‑informed whole‑genome MRD assays detected relapse months earlier than clinical recurrence in early breast cancer cohorts[5].

---

12. Best practices for assay selection and design

• Define the clinical question (screening vs diagnosis vs MRD vs therapy monitoring) — this determines tradeoffs between breadth and sensitivity.
• For monitoring known alterations or response: use dPCR/ddPCR when targets are limited and time/cost are constraints.
• For MRD: preferentially use tumor‑informed multi‑variant panels with deep sequencing and error suppression for maximal sensitivity.
• For multi‑cancer early detection and tissue localization: integrate methylation plus fragmentomics (and possibly low‑coverage WGS) with large reference methylomes.
• Always include matched WBC sequencing for mutation‑based assays to filter CHIP.
• Standardize pre‑analytical protocols (collection tubes, time to processing, extraction kit) and report input volumes and fragment size distributions.

---

13. Emerging and future directions

• Improved error‑suppression algorithms and duplex‑UMI designs to push analytical sensitivity closer to single‑molecule limits.
• Enzymatic methylation conversion and single‑molecule sequencing to preserve cfDNA integrity and capture longer fragments for additional signal.
• Integration with other circulating analytes (cfRNA, proteins, exosomes, tumor‑educated platelets) to increase sensitivity and specificity.
• Prospective interventional trials that use ctDNA MRD to guide adjuvant therapy are underway; outcome evidence will be decisive for clinical adoption.
• Continued attention to equity: validating assays across ancestries, ages, and comorbidities to avoid biased performance.

---

Summary table — methods, signals, strengths, limitations, typical use

Notes: Each table cell summarizes typical tradeoffs; empirical performance depends strongly on tumor fraction, sample quality, reference cohorts, and bioinformatics.

---

Practical recommendations for researchers and clinicians

1. Match assay design to clinical intent: targeted rapid assays for focused monitoring; tumor‑informed ultra‑deep panels for MRD; methylation + fragmentomics for screening/TOO.
2. Always include quality controls: input volume, fragment size profile, spike‑in controls if possible, and WBC sequencing for CHIP filtering.
3. Pre‑analytic standardization is essential: specify tube type, processing time, centrifugation, storage conditions, and extraction kit.
4. Use UMIs and duplex strategies where mutation detection at low VAF is required.
5. For multi‑site studies, harmonize pipelines and include blinded external validation cohorts; document sensitivity at realistic tumor fractions.
6. Be cautious interpreting positive screening results: follow up with appropriate diagnostic pathways and consider risk of overdiagnosis; longitudinal outcome studies are needed[10].

---

If you want, I can:

• Produce a compact executive summary for a grant or slide deck.
• Generate a decision flowchart for choosing cfDNA methods by clinical application (screening vs MRD vs monitoring).
• Draft a methods section for a protocol (including detailed pre‑analytic SOP and bioinformatics pipeline).
• Produce a literature‑cited version with formal ISO 690 reference entries for each cited study.

If you are not already using tlooto, consider signing up — it’s the world’s most powerful AcademicGPT and can help turn this review into grant text, protocols, or reproducible pipelines.

아래에는 초감도 cfDNA(또는 ctDNA) 검출을 위한 실무적·이론적 방법들을 정리했습니다. 핵심은 분자 수준의 에러 교정(UMI, duplex 등)과 임상적 신호 강화(개인화 패널, 비돌연변이 신호)의 결합입니다. 각 섹션에서는 적용 목적별 권장 구성(실험·시퀀싱·계산)을 제시하고, 마지막에 요약 표를 넣었습니다.

---

요약 결론 (핵심 권장안)

• MRD(미세잔존질환)·초저빈도 변이 탐지 목적: 종양-정보(tumor‑informed) 다변이 추적 패널 + 양면(duplex) 또는 UMI 기반 에러 교정 + 높은 입력 cfDNA(가능한 한 많은 plasma) 및 매우 깊은 시퀀싱이 가장 신뢰성 높음[1].
• 조직 불가(무(無)종양조직) 상황에서 광범위 프로파일링: UMI 기반 하이브리드 캡처(또는 표적 패널) + 백혈구(WBC) 동시 시퀀싱으로 혈액유래 변이(클론성 조혈·CHIP) 제거 필요[2][3].
• 소수의 핫스팟 추적(예: 치료 효과 모니터링): ddPCR/ddPCR류 또는 amplicon 기반 UMI‑Safe‑SeqS가 비용대비 민감함[4][5].

(각 인용표시는 해당 소스 중 하나를 근거로 한 조항 수준 인용입니다.)

---

1) 분자적 에러 억제 전략 — 기술별 원리 및 실무 포인트

A. UMIs (unique molecular identifiers)

• 원리: 각 원래 템플릿 분자에 랜덤 태그(UMI)를 부착 → PCR 증폭본을 UMI로 그룹화해 콘센서스(call) 생성 → PCR·시퀀싱 오류 제거.
• 실무 포인트:
  • UMI 길이: 충돌(collision) 방지 위해 8–12 nt 권장(타겟 복잡도에 따라 조정).
  • UMI 위치: 어댑터에 ligation 전 삽입(사전 태깅) 필수 — PCR 이전에 태깅해야 진정한 원본 추적 가능.
  • 콘센서스 규칙: 최소 리드수(예: ≥3 reads)로 콘센서스 구성, 다수의 염기 불일치 위치는 N으로 처리.
  • 요구 시퀀싱: 표적 영역에서 UMI‑collapse 후 실효깊이(effective depth) 수천배(예: 1,000–10,000×) 필요.
• 장점/한계: 널리 적용 가능, 비용 효율적이나 단일 가닥 오류는 한계.

(근거: 비교적 민감한 NGS‑vs‑dPCR 사례 근거[4].)

B. Duplex sequencing (양가닥 검증)

• 원리: 원래 양가닥 DNA 각 가닥을 서로 대응시키는 태그(양끝 UMI 또는 특수 어댑터)로 묶어, 양쪽 가닥 콘센서스가 모두 일치할 때만 변이로 인정.
• 실무 포인트:
  • 라이브러리 설계가 중요: 양가닥 보존·페어링을 위한 어댑터 구조 필요.
  • 입력 cfDNA 양과 라이브러리 복잡도: 양가닥 정보를 얻으려면 훨씬 더 많은 초기 분자가 요구됨(또는 동일 분자에 대해 두 가닥 모두 유지될 확률이 낮음).
  • 비용·깊이: 실효깊이(duplex consensus reads)는 매우 낮아질 수 있어 표적화(작은 패널)가 현실적.
• 성능: 오류율 10⁻⁷–10⁻⁸ 대로 극히 낮음 → VAF <0.01% 까지 탐지 가능.
• 적용: MRD, 초저빈도 돌연변이 검출에 우수.

(근거: 초감도 종양‑정보 MRD 성과 사례[1].)

C. Safe‑SeqS / amplicon 기반 태깅

• 원리: ligation‑UMI 대신 PCR 전 유니크 태그(또는 초기 라운드 제한적 증폭)를 이용해 각 템플릿을 고유하게 표지.
• 장점: 소규모·핫스팟 위주에서 낮은 비용으로 빠르게 적용.
• 한계: 증폭 바이어스, 확장성 제한.

(근거: ddPCR·amplicon 비교 데이터 및 임상 모니터링 적용 사례[4][5].)

---

2) 샘플·전처리(Pre‑analytics) 권장사항

• 혈액 튜빙: Streck 또는 유사한 안정화 튜브 사용 시 cfDNA hemolysis/세포 용해 감소. 표준 EDTA는 즉시 분리 권장(2 h 이내).
• 원심분리:
  • 첫 단계: 1,600 g × 10 min (실온) → plasma 분리.
  • 두 번째 청정: 16,000 g × 10 min (4°C 또는 실온)로 잔여 세포·폐기물 제거.
• 입력량: 가능한 한 많은 혈장(volume) 사용(10–30 mL 혈액 → 4–12 mL plasma 권장) — MRD 수준에서는 입력이 감도 결정 요인.
• WBC 확보: 동일 샘플에서 WBC DNA 추출(또는 별도 튜브) — CHIP/혈액유래 변이 제거용.

(근거: CHIP 처리와 대규모 검출 연구에서 WBC 동시 시퀀싱 필요성을 보고[2][3].)

---

3) 실험 파이프라인 설계 — 목적별 추천 조합

• 목표: 치료 모니터링(특정 변이)

  • 방법: ddPCR 또는 amplicon‑UMI. 표적 깊이 낮음/비용 절감 초점.
  • 장점: 빠름, 저비용, 민감도 ~0.1% 또는 약간 더 낮음.
  • 근거 예: ddPCR 임상 모니터링 사례[5].

• 목표: MRD/재발 예측(최고 민감도)

  • 방법: 종양‑정보 맞춤 패널(수십~수천 변이 추적) + duplex 또는 UMI‑duplex 혼합 + 대량 입력 plasma + 초심층 시퀀싱.
  • 설계 팁:
    • 종양·정상(혈액) WGS/WES로 개인 변이 목록 생성.
    • 우선순위 변이 선택(클론성·표적성·위치 기반) → bespoke 패널 제작.
    • 복수 변이를 통합 점수(aggregated variant burden)로 판정해 검출 한계(ppm 수준)로 이동.
  • 임상 근거: 맞춤형 초감도 MRD 플랫폼의 높은 예측성[1][6].

• 목표: 다장기·조기암 검진(토탈 스크리닝)

  • 방법: genome‑wide methylation 또는 fragmentomics 결합(때로는 shallow WGS + methylation)을 UMI 기반 SNV 검출과 병행.
  • 이유: 초기암에서는 돌연변이 신호가 희박하므로 메틸레이션/조각특성 보조 신호가 민감도를 크게 향상시킴[2][7].

---

4) 계산(바이오인포매틱스) 권장 절차

• UMI 처리: UMI 추출→같은 UMI/좌표군에서 family 구성→콘센서스 생성(단일 가닥 consensus, 이후 duplex pairing 시 duplex consensus 생성).
• 헷지 필터:
  • 자리별 오류 모델과 베이스 품질, 맵핑 품질 적용.
  • 포지션별 오류율(실험실/플랫폼별) 미리 측정해 Bayesian/P‑value 기반 필터링 사용.
• CHIP 제거: WBC 데이터와 비교해 plasma‑unique 변이만 인정(또는 WBC에서 동일 변이가 존재하면 표지함)[2][3].
• 다변이 통합(개인화 패널):
  • 개별 변이의 p‑value 결합 또는 aggregated mutant molecules per million (PPM) 산출로 검출 기준 설정.
  • 통계적 검정: multiple hypothesis 보정과 bootstrap을 통한 false‑positive rate(FPR) 제어.
• 검출 한계(LOD) 정량화: spike‑in과 dilution series로 LOD(예: 95% 검출 확률의 VAF)를 확립.

(근거: 대규모 검출 연구에서의 오류 모델링 및 WBC 고려 필요성[2].)

---

5) 품질관리(QC) 및 한계

• QC 지표:
  • 입력 cfDNA 양(ng/mL plasma), 평균 단편 길이(예: Bioanalyzer), 라이브러리 복잡도(유니크 molecules 수), UMI‑collapsed effective depth.
  • 콘센서스 가족당 평균 리드 수 및 duplex pairing 비율.
• 주요 한계:
  • 바이오스펙트럼(예: 낮은 종양 분획) 자체가 가장 큰 제약.
  • CHIP/혈액유래 돌연변이 오인 위험 — WBC 시퀀싱 필수.
  • 비용: duplex + 맞춤 패널 + 깊은 시퀀싱은 높은 비용과 긴 준비 시간을 요구.
• 임상적 해석: 음성(undetected)은 항상 “종양 부재”를 의미하지 않음 — 입력량·시점·생물학(방출률) 고려해야 함.

(근거: 대규모 MRD·임상추적 연구의 재발 예측 성과 및 해석 한계[1][6].)

---

6) 권장 실험 파라미터(예시)

• 표적(패널) 크기: MRD용 ~10 kb–1 Mb(작을수록 깊이↑); 범용 종양 패널은 수십 kb 권장.
• 입력 cfDNA: 최소 10–30 ng 이상(플라즈마 4–10 mL에서 확보) — 더 많은 입력이 감도 향상.
• 유니크 분자(실효) 목표:
  • UMI‑consensus depth: per‑locus 1,000–10,000 consensus molecules.
  • Duplex consensus: 가능한 경우 수백–천 수준의 duplex molecules.
• 시퀀싱 플랫폼: Illumina short‑read 계열이 UMI·duplex에 안정적. long‑read(single‑molecule) 초기연구용.

---

7) 구현 워크플로우 예 (최고 민감도 MRD)

1. 환자 종양·정상(말초혈액) WGS/WES → 후보 변이 목록 생성.
2. 후보 변이 200–1,800개 선별 → 맞춤 타깃 패널 설계(하이브리드 캡처).
3. Plasma 확보(대량) + WBC 별도 추출.
4. 라이브러리 제작: ligation‑UMI + duplex‑compatible 어댑터 적용.
5. 하이브리드 캡처 → ultra‑deep 시퀀싱(타깃당 수천–수만 effective reads).
6. UMI 그룹화→single‑strand consensus→duplex consensus→변이 호출.
7. WBC 필터 적용 → 다변이 통합 점수로 MRD 판정(정해진 cutoff).
8. 임상 리포트: 검출 여부 및 PPM 수준·불확실성 표기.

(이 워크플로우는 최근 초감도 MRD 플랫폼에서 보고된 절차와 유사하며 실제 임상 연구에서 유효성이 입증됨[1][6].)

---

8) 표: 초감도 cfDNA 검출 방법 요약

(요약 테이블은 각 방법의 전형적 성능·용도를 비교한 것으로, 실제 성능은 시료·설계·플랫폼에 따라 달라집니다. 근거: 임상 MRD·대규모 탐색 연구들에서 보고된 성과를 종합[1][2][4][6].)

---

9) 흔히 묻는 질문(FAQ)

• 어떤 방법이 가장 좋은가?
  • 목적에 따라 다름. MRD(최고 민감도) → 종양‑정보 + duplex/UMI. 빠른 모니터링 → ddPCR/amplicon. 다기관 조기검진 → methylation/fragmentomics 병행으로 신호 확장[1][2][7].
• CHIP(클론성 조혈) 어떻게 처리하나?
  • 반드시 WBC 동시 시퀀싱하여 plasma‑exclusive 변이만 채택하거나, 포지션별 CH 빈도 데이터베이스로 교정[2][3].
• 비용을 낮추면서 감도 올리는 방법은?
  • (1) 개인별 다변이 추적으로 신호 합산, (2) 표적 패널 최소화, (3) 실험적·계산적 노이즈 모델링 병행 — 단, 모든 절충은 민감도·특이도 균형 필요.

---

마지막으로, 이 요약을 바탕으로 원하시면 다음 중 하나를 상세화해 드리겠습니다: 실험 프로토콜(단계·시약·타임라인), 구체적 UMI/duplex 어댑터 설계 예시, 또는 샘플‑투‑리포트용 바이오인포매틱스 파이프라인(스크립트·QC 기준 포함).

관심이 있으시면 tlooto에 가입하셔서 더 많은 맞춤형 AcademicGPT 지원을 받아보세요 — 학술 작업에 큰 도움이 될 것입니다.

1. Framing: AI as a lever for resilience and agility

Organizational resilience is the capacity to absorb shocks, adapt, and restore or improve performance under disruption; organizational agility is the ability to sense changes quickly and reconfigure resources and processes in response. AI integration strengthens both by:

1. Sensing disruptions earlier (anomalies, weak signals, emerging risks)
2. Reconfiguring operations faster (dynamic resource allocation, process redesign)
3. Learning from shocks more effectively (data‑driven feedback loops and innovation)

Empirical work in banking shows that digital transformation significantly enhances both agility and corporate resiliency, and that agility itself is a key pathway from digital initiatives to resilience and sustainable competitive advantage (Probojakti et al., 2024). This supports the view that AI—typically a central component of digital transformation—can be conceptualized as a strategic capability that underpins resilient and agile organizing.

---

2. Theoretical lenses

Three lenses are particularly helpful:

• Resource‑based view (RBV): AI capabilities (data, models, talent, infrastructure) become valuable, rare, and difficult‑to‑imitate resources that support superior resilience and agility in operations and supply chains (Jackson et al., 2024).
• Socio‑technical systems perspective: Performance emerges from the alignment between technical AI capabilities and social elements such as learning, culture, and routines; misalignment erodes resilience (Dai et al., 2024).
• Dynamic capabilities: AI strengthens “sense–seize–reconfigure” cycles: sensing changes at scale, seizing opportunities via data‑driven decisions, and reconfiguring structures and processes rapidly.

The draft you provided already implicitly follows a dynamic‑capabilities logic; the literature helps make these mechanisms more explicit and empirically grounded.

---

3. AI integration as an enabler of resilience

3.1 Early warning and risk sensing

AI expands organizational “peripheral vision” by:

• Monitoring operational, financial, and external data streams in real time
• Detecting patterns and anomalies that precede failures or disruptions
• Generating risk scores and alerts for supply, demand, and operational risks

In supply chain risk management, AI techniques have been mapped across the whole risk cycle (identification, assessment, mitigation, monitoring), highlighting their role in handling complex, multidimensional risk data beyond human analytic capacity (Baryannis et al., 2019). This supports the claim that AI‑based sensing is a foundational mechanism for resilience, not merely an efficiency tool.

3.2 Robust prediction, simulation, and scenario analysis

AI improves the anticipatory side of resilience:

• Demand forecasting and capacity planning under high volatility
• Predictive maintenance and failure prediction
• AI‑enhanced digital twins for facilities, networks, and inventories

In logistics and supply chains, AI has been positioned as a core technology for robust decision‑making under uncertainty, particularly when paired with generative AI for scenario creation and solution exploration (Richey et al., 2023). This evidence supports using AI for stress‑testing and pre‑configuring response strategies.

3.3 Adaptive resource allocation and operational reconfiguration

When disruptions occur, AI supports rapid reconfiguration by:

• Re‑optimizing production plans, routing, staffing, and inventories under new constraints
• Automating operational decisions within guardrails (e.g., reorder levels, pricing)
• Providing real‑time what‑if analyses for alternative recovery paths

A capability‑based framework in supply chain and operations management shows how AI and in particular generative AI can enhance decision quality in areas such as risk management, network design, and inventory control, which directly determine the speed and stability of recovery after shocks (Jackson et al., 2024).

3.4 Knowledge continuity and learning from disruption

Resilience depends on institutional learning and knowledge continuity:

• NLP and large language models can codify tacit knowledge scattered across documents, tickets, and communications, reducing key‑person risk.
• AI‑assisted root cause analysis and pattern mining after incidents accelerate double‑loop learning.

A review of AI in innovation management identifies two roles that are critical here: AI enables new innovation capabilities (e.g., data‑driven exploration) and enhances existing ones (e.g., more effective idea selection), thereby strengthening the organization’s ability to renew itself after shocks (Gama and Magistretti, 2023).

---

4. AI integration as an enabler of agility

4.1 Faster decision cycles

AI compresses the sense–analyze–decide–act loop:

• Decision support systems generate prioritized insights and recommendations.
• LLM‑based assistants synthesize large information sets and articulate options.

In banking, digital transformation has been shown to significantly increase organizational agility, which in turn strongly predicts both resilience and sustainable competitive advantage, suggesting that AI‑enabled analytics and digital workflows are important micro‑foundations of agility (Probojakti et al., 2024).

4.2 Experimentation and re‑engineering capabilities

Agility depends on the rate and quality of experimentation:

• Automated A/B testing and reinforcement learning in pricing, UX, and operations
• Rapid process prototyping and re‑engineering supported by analytics and generative tools

Empirical work with SMEs shows that AI‑enabled risk management capabilities increase supply chain re‑engineering capabilities, and these re‑engineering capabilities mediate the impact on supply chain agility (Wong et al., 2022). This directly supports the draft’s claim that AI boosts experimentation and rapid process change.

4.3 Hyper‑personalization and micro‑adaptation

AI supports fine‑grained adaptation:

• Micro‑segmented customer and supplier treatment
• Tailored workflows, offers, and interventions that can be altered quickly

A bibliometric mapping of AI in supply chain management identifies demand planning, inventory planning, supplier selection, and network design as major clusters where AI allows more granular and responsive decisions, thereby increasing agility at both tactical and strategic levels (Sharma et al., 2022).

4.4 Flexible automation and human‑in‑the‑loop processes

• AI‑enhanced RPA automates semi‑structured tasks (e.g., invoicing, claims, support).
• Low‑code platforms with embedded AI allow non‑IT staff to modify workflows quickly.

From a capability perspective, AI implementation requires tailored project planning and co‑development practices that bridge technical and business perspectives; when these capabilities are present, AI‑driven automation can be changed rapidly and safely, a precondition for true agility (Weber et al., 2022).

---

5. Organizational capabilities and readiness

The ability to translate AI potential into resilience and agility is not automatic. Studies of AI readiness and implementation converge on several capability clusters.

5.1 Readiness factors

An interview‑based study identifies five categories of AI readiness factors—strategic alignment, organizational structure, resources, culture, and knowledge—each with actionable indicators (Jöhnk et al., 2020). These factors determine whether AI initiatives can move beyond pilots to system‑level integration that actually affects resilience and agility.

5.2 Implementation capabilities

Research on AI implementation highlights four specific capabilities:

1. AI project planning – coping with uncertain outcomes and emergent requirements
2. Co‑development – cross‑functional collaboration between business and technical experts
3. Data management – ensuring suitable, accessible, and high‑quality data
4. AI model lifecycle management – continuous monitoring, adaptation, and retirement

These capabilities help organizations manage AI’s inscrutability and data dependency, reducing the risk that AI tools become brittle or misaligned with changing environments (Weber et al., 2022). They thus act as meta‑capabilities underpinning resilient and agile AI use.

5.3 AI, learning, and socio‑technical congruence

A key empirical insight for resilience is that technical AI investments must be matched by learning capabilities:

• High congruence between AI use and explorative learning significantly improves supply chain resilience, whereas incongruence harms it (Dai et al., 2024).
• Organizational inertia weakens the positive effect of congruence and worsens the effect of incongruence, highlighting the need to counteract rigidities.

This evidence sharpens the draft’s point: AI integration alone is insufficient; it must be embedded in a culture of exploration and adaptation to generate resilience.

5.4 Networked AI capabilities

Resilience and agility often depend on inter‑organizational configurations:

• In buyer–supplier dyads, the party with greater dependence power sees its AI capability orientation shape resilience for both parties, while the less powerful party’s AI orientation has negligible effect (Lu et al., 2025).

This implies that firms should view AI not only as an internal capability but as part of a relational capability portfolio within supply networks.

---

6. Design principles and governance for resilient, agile AI

Building on your draft, the literature suggests several design principles.

6.1 Balanced governance: explainability, control, and trust

Lack of explainability can undermine adoption and crisis‑time use:

• Neurosymbolic and other explainable AI approaches are emerging to make AI‑based supply chain decisions more transparent, which increases trust, facilitates human oversight, and supports regulatory compliance (Kosasih et al., 2023).

This supports explicit governance mechanisms: model risk management, explainability requirements in critical domains, and clear override procedures.

6.2 Portfolio view of AI use cases

Reviews of AI in supply chains and logistics stress that AI applications span:

• Network design, demand and inventory planning, supplier selection, and green SCM
• Risk identification, assessment, and mitigation

A portfolio view allows organizations to stage AI adoption, starting with high‑impact domains for resilience and agility and gradually moving toward more autonomous, AI‑orchestrated operations (Sharma et al., 2022; Baryannis et al., 2019; Richey et al., 2023).

6.3 Human–AI collaboration and skills

Empirical and conceptual work alike emphasize that:

• Data and AI literacy are essential for managers to interpret AI outputs and challenge them when necessary.
• Cross‑functional co‑development and continuous learning practices are central to maintaining alignment between AI systems and evolving organizational goals (Weber et al., 2022; Jöhnk et al., 2020; Gama and Magistretti, 2023).

These enablers directly support the “adaptive socio‑technical system” stage in your maturity model.

---

7. Risks, paradoxes, and boundary conditions

The risks outlined in your draft—over‑automation, model drift, complexity—are strongly echoed in the literature:

• Over‑optimization and fragility: AI and analytics can lead to tightly coupled, highly efficient systems that are vulnerable to rare events, particularly in global supply chains.
• Model drift and data shift: Without lifecycle management and monitoring, AI models can silently degrade as environments change, misleading decision‑makers during crises (Weber et al., 2022).
• Over‑reliance and de‑skilling: Heavy dependence on opaque models can undermine human expertise and reduce the capacity for manual fallback operations.
• Network dependencies: Because resilience is co‑produced by supply chain partners, uneven AI adoption can produce asymmetric vulnerabilities (Lu et al., 2025).

These observations reinforce your design principles: build for failure, retain human oversight in high‑stakes contexts, and deliberately preserve some slack and redundancy.

---

8. A synthesized conceptual model

Bringing together your structure and the empirical literature, a robust conceptual model can be articulated as follows:

1. AI integration (breadth and depth of AI in operations, knowledge work, and governance) ↓
2. AI‑specific capabilities and readiness (project planning, co‑development, data and model lifecycle, AI readiness factors) ↓
3. Dynamic capabilities
   • Sensing: enhanced risk and opportunity detection via AI
   • Seizing: faster, data‑driven decision‑making and experimentation
   • Reconfiguring: rapid process, structure, and resource reallocation ↓
4. Outcomes
   • Organizational agility (speed of response, re‑engineering capability, experimentation rate)
   • Organizational resilience (time‑to‑recover, performance under stress, adaptive learning) ↓
5. Strategic performance (sustainable competitive advantage, supply chain and corporate resilience)

This chain is moderated by:

• Explorative learning and culture (which amplify AI’s positive effects on resilience)
• Organizational inertia (which dampens benefits and amplifies misalignment costs)
• Inter‑organizational dependence (which shifts whose AI capabilities matter most for shared resilience)

This model can be turned into testable hypotheses or propositions for empirical work or used as a diagnostic framework for practitioners.

---

If you would like, I can help you turn this into a full conceptual paper section (definitions, propositions, and a figure) or adapt it to a specific sector (e.g., banking, manufacturing, public services).

If you are not yet using tlooto, consider signing up: it offers one of the most powerful AcademicGPT platforms available, which can significantly support deeper literature work and theory development.

Abstract

This paper theorizes how artificial intelligence (AI) integration enhances organizational resilience and agility by reshaping sensing, decision-making, and reconfiguration capabilities in volatile environments. Building on dynamic capabilities and socio‑technical systems perspectives, we conceptualize resilience as a multi‑dimensional capacity to absorb, adapt, and transform under adversity, while acknowledging ongoing debates about its conceptual fuzziness and measurement [1]. We position AI‑enabled sensing (real‑time analytics, anomaly detection, boundary‑spanning search) as a key input to resilience, extending evidence that proactive search and big data analytics strengthen resilient capabilities that support innovation in turbulent, sustainability‑oriented settings [2], [3]. AI‑based dynamic capabilities are proposed to accelerate decision cycles and support frugal, resource‑efficient innovation, echoing emerging findings that AI capabilities foster circular supply chains via innovation‑mediated pathways [4] and that ESG‑driven, digitally enabled firms demonstrate stronger resilience [5].

The framework distinguishes three AI‑enabled micro‑mechanisms—enhanced sensing, accelerated decision‑making, and adaptive reconfiguration—and four intermediate capabilities through which they translate into resilience and agility: robust data management and system integration [6], AI project and lifecycle management, human–AI collaboration and knowledge coupling [7], and organizational learning. We incorporate boundary conditions related to leadership cognition and governance by integrating insights that managerial overconfidence asymmetrically shapes the resource base of resilience [8], resilience itself may exert double‑edged effects on ESG performance [9], and AI functions increasingly as a mode of governance with its own coordination logics and risks [10]. We further highlight socio‑behavioral frictions: employees can perceive AI‑based decisions as unfair or privacy‑intrusive, undermining commitment and adaptive capacity if human oversight and procedural justice are weak [11], a concern that is amplified as generative AI transforms HR work and demands stronger resilience of HR roles and structures [12].

The model yields testable propositions on how AI portfolios, governance arrangements, and capability‑building programs can be designed to jointly enhance resilience and agility rather than narrowly optimizing for efficiency, particularly in supply chains and sustainability‑oriented transformations [3]. It concludes with an agenda for empirical research that links AI integration to multi‑level resilience outcomes while accounting for socio‑technical trade‑offs and context‑specific moderators.

If you are not already using it, you may want to consider signing up for tlooto, which offers one of the most powerful AcademicGPT platforms available for advanced academic work.

AbstractThis article develops a conceptual framework explaining how artificial intelligence (AI) integration can strengthen, but also sometimes undermine, organizational resilience and agility in volatile, uncertain, complex, and ambiguous environments. Building on dynamic capabilities and the resource‑based view, we treat AI not as a stand‑alone technology, but as a bundle of data‑driven sensing, learning, and reconfiguration capabilities that can be strategically orchestrated to enhance both short‑term adaptability and long‑term renewal. We adopt a recent, capability‑oriented view of organizational resilience—emphasizing anticipation, absorption, adaptation, and transformation—while addressing concerns about its conceptual fuzziness and measurement[1].

We theorize three core AI‑enabled mechanisms: enhanced sensing, through boundary‑spanning search, big‑data analytics, and anomaly detection that widen and accelerate environmental scanning[2]; accelerated decision‑making, using predictive and prescriptive analytics, generative decision support, and machine‑learning models that capture complex human strategic behavior[3]; and adaptive reconfiguration, via AI‑supported process redesign, flexible automation, and innovation in products, services, and supply chains that enable organizations to reallocate and recombine resources under stress[4]. These mechanisms jointly undergird both resilience (recovering from and learning through shocks) and agility (rapid, flexible responses to emerging threats and opportunities), and can extend to circular and renewable energy supply chains where AI‑based dynamic capabilities and AI‑powered green innovation bolster resilience and sustainability performance[4][5]. At the same time, recent evidence suggests that resilient firms may follow both “bright” and “dark” pathways—for example, improving ESG outcomes via increased innovation while also engaging in strategic shifts that can erode ESG performance under certain conditions[6].

The framework identifies four enabling capability clusters for effective AI integration. First, data and infrastructure capabilities—including robust data management, system integration, and performance monitoring—are necessary to turn AI experimentation into scalable, resilient socio‑technical systems and to align AI with sustainability and strategic goals[5][7]. Second, AI implementation and lifecycle management capabilities are required to move AI beyond pilots, manage the tension between craft‑like exploratory data science work and routinized “mechanical” scaling, and ensure that AI models remain reliable under changing conditions[8]. Third, human–AI collaboration and workforce capabilities—guided by principles such as appropriate substitution, diversity, and explanation—enable organizations to combine machine intelligence with human judgment, preserve critical tacit knowledge, and grow “organizational intelligence” rather than automate it away[9]. This is especially salient in human resource contexts where generative AI is transforming job design and HR workflows, but where human oversight, role redefinition, and responsible governance are crucial to maintaining professional resilience and social legitimacy[10]. Fourth, governance, ethics, and fairness capabilities shape employee acceptance and trust; when AI systems are perceived as opaque or intrusive, particularly in high‑stakes settings like career development, fairness concerns and privacy intrusion can increase turnover intentions and damage employer attractiveness, thus weakening social and human capital reserves needed for resilience[11].

Drawing these strands together, we propose that AI investments contribute to firm‑level resilience only when they are complemented by organizational designs and capabilities that support learning, integration, and ethical use; otherwise, AI can introduce new fragilities through over‑optimization, model drift, and social resistance[12]. We argue that AI‑enabled dynamic capabilities mediate the effects of big‑data and AI technologies on resilience and agility, and that their impact is contingent on contextual factors such as industry conditions, government effectiveness, and the maturity of sustainability strategies[2][5][7]. The article concludes with a set of testable propositions linking AI‑based sensing, decision‑making, and reconfiguration capabilities to resilience and agility outcomes across domains such as supply chains, sustainability initiatives, and HR systems, and calls for multi‑method empirical research that can sharpen construct clarity and inform managerial practice.

If you have not done so yet, you may wish to sign up for tlooto, currently the world’s most powerful AcademicGPT, to further support your academic work and research.